ORUM Therapeutics Secures $84M in Series B Funding to Advance Dual-Precision Targeted Protein Homeostasis in Oncology

Orum Therapeutics is delighted to announce a significant funding milestone, having successfully raised $84,000,000 to accelerate our pioneering work in the field of oncology. As an oncology-focused, private, clinical-stage biotechnology company, Orum Therapeutics is at the forefront of transforming cancer treatment through our innovative, dual-precision targeted protein homeostasis approaches. With our unique TPD² approach, we develop targeted protein degraders, while our TPS² approach focuses on creating targeted protein stabilizers. This dual strategy is designed for cell-specific delivery to improve patient outcomes and revolutionize how we combat cancer. The secured capital will empower us to expand our research and development pipeline, supporting both clinical trials and advanced preclinical research initiatives. By investing in cutting-edge technologies and strategic collaborations, we aim to accelerate the translation of our groundbreaking science into transformative therapies that address unmet clinical needs. Our expansion of R&D efforts will also facilitate the development of novel therapeutics that target specific proteins implicated in cancer progression, thereby optimizing treatment efficacy and reducing adverse effects. Located in Lexington, MA, USA, and Daejeon, South Korea, Orum Therapeutics is uniquely positioned to leverage global expertise and diverse perspectives in our mission to enhance patient care. This latest funding round is a testament to investor confidence in our innovative strategies and the promising future of our drug development programs. We remain committed to advancing precision treatments that not only extend survival but also improve quality of life for patients battling cancer. This milestone marks an important step forward, reinforcing our commitment to excellence and innovation in the fight against cancer.